Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RAD001 + Docetaxel in Metastatic Androgen Independent Prostate Cancer
NCT00459186Phase 2Completed
- Sponsor
- Dana-Farber Cancer Institute
- Start
- Nov 2005
- Primary completion
- Dec 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of everolimus in metastatic castration-resistant prostate cancer (mCRPC), sponsored by Dana-Farber Cancer Institute. Primary endpoint: Number of Patients Free of Dose Limiting Toxicity at 21 days. Started Nov 2005; status: completed.
02
Drugs
everolimus
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT00459186.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00459186.